{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:40:18Z","timestamp":1781332818296,"version":"3.54.1"},"reference-count":41,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"name":"National Health and Medical Research Council Centre of Research Excellence in Tuberculosis","award":["APP1153493"],"award-info":[{"award-number":["APP1153493"]}]},{"name":"National Health and Medical Research Council Centre of Research Excellence in Tuberculosis","award":["APP1157643"],"award-info":[{"award-number":["APP1157643"]}]},{"DOI":"10.13039\/100007224","name":"National Foundation for Science and Technology Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring may optimise treatment outcomes in patients with multidrug-resistant tuberculosis, yet current methods are invasive and resource intensive. This study evaluated the feasibility of using saliva point-of-care testing to screen for suboptimal exposure to levofloxacin and linezolid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a community-based cross-sectional study in Vietnam (2021\u20132023). Drug concentrations were measured in paired plasma and saliva samples at 0, 2 and 5\u2005h post-dose, using a point-of-care test (NanoPhotometer NP80) in comparison with liquid chromatography-mass spectrometry. Drug exposure (area under the drug concentration\u2013time curve from 0 to 24\u2005h (AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      )) was calculated using a Bayesian population pharmacokinetic approach (Edsim++). Therapeutic targets were defined as a free AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      to minimum inhibitory concentration ratio of 160 for levofloxacin and 125 for linezolid. Receiver operating characteristic curve analyses were conducted to determine optimal saliva thresholds for predicting subtherapeutic or supratherapeutic plasma exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A saliva exposure threshold of 70.3\u2005mg\u00b7h\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      accurately identified 16 out of 19 patients with subtherapeutic levofloxacin plasma exposure (sensitivity 84%, specificity 78%; n=60). For linezolid (n=17), saliva testing correctly identified the only patient with subtherapeutic exposure and the only patient with supratherapeutic exposure. However, no saliva exposure thresholds could be determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Saliva-based point-of-care testing may predict the plasma drug exposure of levofloxacin and linezolid, thus enabling the detection of patients at risk of suboptimal drug exposure. This non-invasive tool warrants further investigation to establish a saliva-based threshold for linezolid and to evaluate the clinical impact and cost-effectiveness of saliva-guided drug dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01875-2025","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:35:15Z","timestamp":1769103315000},"page":"2501875","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Saliva point-of-care testing for suboptimal levofloxacin and linezolid exposure in multidrug-resistant tuberculosis"],"prefix":"10.1183","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8508-8990","authenticated-orcid":false,"given":"Thi A.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luong V.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-6716","authenticated-orcid":false,"given":"Hoa D.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8496-1906","authenticated-orcid":false,"given":"Tram N.B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieko C.","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2026061210150888000_67.6.2501875.1","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: Module 4: treatment \u2013 drug-resistant tuberculosis treatment, 2022 update. 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240063129 Date last accessed: 16 January 2026."},{"key":"2026061210150888000_67.6.2501875.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03463-2020"},{"key":"2026061210150888000_67.6.2501875.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02107-2018"},{"key":"2026061210150888000_67.6.2501875.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2026061210150888000_67.6.2501875.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae388"},{"key":"2026061210150888000_67.6.2501875.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"2026061210150888000_67.6.2501875.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31882-3"},{"key":"2026061210150888000_67.6.2501875.8","unstructured":"World Health Organization . Implementing the End TB Strategy: the essentials, 2022 update. 2022. www.who.int\/publications\/i\/item\/9789240065093 Date last accessed: 16 January 2026."},{"key":"2026061210150888000_67.6.2501875.9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40262-024-01346-7","article-title":"Salivary therapeutic drug monitoring of antimicrobial therapy: feasible or futile?","volume":"63","author":"Davies Forsman","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2026061210150888000_67.6.2501875.10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/jac\/dkaa420","article-title":"A mobile microvolume UV\/visible light spectrophotometer for the measurement of levofloxacin in saliva","volume":"76","author":"Alffenaar","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026061210150888000_67.6.2501875.11","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkab075","article-title":"Saliva-based linezolid monitoring on a mobile UV spectrophotometer","volume":"76","author":"Kim","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026061210150888000_67.6.2501875.12","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw164"},{"key":"2026061210150888000_67.6.2501875.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01903-2019"},{"key":"2026061210150888000_67.6.2501875.14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/jac\/dkab057","article-title":"Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania","volume":"76","author":"Mohamed","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026061210150888000_67.6.2501875.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02164-18"},{"key":"2026061210150888000_67.6.2501875.16","doi-asserted-by":"crossref","first-page":"e70051","DOI":"10.1002\/sscp.70051","article-title":"Simultaneous quantification of levofloxacin and linezolid in human plasma and saliva using liquid chromatography quadrupole-Orbitrap mass spectrometry","volume":"8","author":"Nguyen","year":"2025","journal-title":"Sep Sci Plus"},{"key":"2026061210150888000_67.6.2501875.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.017"},{"key":"2026061210150888000_67.6.2501875.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01092-18"},{"key":"2026061210150888000_67.6.2501875.19","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/cid\/ciy611","article-title":"Levofloxacin pharmacokinetics\/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026061210150888000_67.6.2501875.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.05.010"},{"key":"2026061210150888000_67.6.2501875.21","doi-asserted-by":"crossref","first-page":"106999","DOI":"10.1016\/j.ijantimicag.2023.106999","article-title":"Protein binding investigation of first-line and second-line antituberculosis drugs","volume":"62","author":"Fage","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026061210150888000_67.6.2501875.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00239-2022"},{"key":"2026061210150888000_67.6.2501875.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001721"},{"key":"2026061210150888000_67.6.2501875.24","unstructured":"World Health Organization . Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. 2018. www.who.int\/publications\/i\/item\/WHO-CDS-TB-2018.5 Date last accessed: 16 January 2026."},{"key":"2026061210150888000_67.6.2501875.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00343-17"},{"key":"2026061210150888000_67.6.2501875.26","doi-asserted-by":"crossref","first-page":"1032674","DOI":"10.3389\/fphar.2022.1032674","article-title":"Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026061210150888000_67.6.2501875.27","unstructured":"World Health Organization . High-priority target product profiles for new tuberculosis diagnostics. Report of a consensus meeting, 28\u201329 April 2014, Geneva, Switzerland. 2014. www.who.int\/publications\/i\/item\/WHO-HTM-TB-2014.18 Date last accessed: 16 January 2026."},{"key":"2026061210150888000_67.6.2501875.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01925-2021"},{"key":"2026061210150888000_67.6.2501875.29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00125711"},{"key":"2026061210150888000_67.6.2501875.30","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40262-024-01398-9","article-title":"Can we predict drug excretion into saliva? A systematic review and analysis of physicochemical properties","volume":"63","author":"Nguyen","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2026061210150888000_67.6.2501875.31","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/jac\/dkaf169","article-title":"High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid","volume":"80","author":"Kawasuji","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026061210150888000_67.6.2501875.32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/rccm.202407-1354OC","article-title":"Efficacy and safety of higher doses of levofloxacin for multidrug-resistant tuberculosis: a randomized, placebo-controlled phase II clinical trial","volume":"211","author":"Phillips","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061210150888000_67.6.2501875.33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/bdd.2294","article-title":"Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy","volume":"42","author":"Boonpeng","year":"2021","journal-title":"Biopharm Drug Dispos"},{"key":"2026061210150888000_67.6.2501875.34","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/bcp.15102","article-title":"Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients","volume":"88","author":"Tietjen","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026061210150888000_67.6.2501875.35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00279-19"},{"key":"2026061210150888000_67.6.2501875.36","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1111\/bcp.15368","article-title":"Parametric population pharmacokinetics of linezolid: a systematic review","volume":"88","author":"Qin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026061210150888000_67.6.2501875.37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-18"},{"key":"2026061210150888000_67.6.2501875.38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00393-16"},{"key":"2026061210150888000_67.6.2501875.39","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.2147\/IDR.S389442","article-title":"Population pharmacokinetics of levofloxacin and moxifloxacin, and the probability of target attainment in Ethiopian patients with multidrug-resistant tuberculosis","volume":"15","author":"Sidamo","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2026061210150888000_67.6.2501875.40","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ijid.2020.01.041","article-title":"Precision and personalized medicine and anti-TB treatment: is TDM feasible for programmatic use?","volume":"92S","author":"Alffenaar","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2026061210150888000_67.6.2501875.41","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03999-2020"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01875-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:15:18Z","timestamp":1781284518000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01875-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1183\/13993003.01875-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01875-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}